MGTX stock eases after strong Q2 revenue surprise and turnaround

Published on 09/03/2026 at 18:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MGTX stock closed slightly lower on September 2, 2026, after MeiraGTx delivered a sharp revenue and earnings surprise in Q2 2026 that pushed the shares up more than 78% since the start of the year.

MGTX stock ended the last trading session at 14.06 USD on September 2, 2026, leaving MeiraGTx Holdings plc (ISIN US58550P1012) with a year-to-date gain of 78.14% despite a modest 0.85% decline on the day, according to market data from Zonebourse.

Q2 2026 figures mark a clear turnaround

According to a results summary compiled by Zonebourse, MeiraGTx published its results for the second quarter of 2026 for the period ended June 30, 2026.

In Q2 2026, MeiraGTx reported revenue of 321,434 USD, far above the consensus estimate of 10.4 million USD referenced in the same data overview and representing a sharp upside surprise compared with Q1 2026 revenue of 0.29 million USD.

The same flash results note that MeiraGTx delivered net income of 1.71 USD per share in Q2 2026, compared with a FactSet consensus that had expected a loss of 0.35 USD per share, indicating an earnings beat of 2.06 USD per share versus expectations.

Stock performance and trading context

Market data on the MeiraGTx quote page at Zonebourse show that the closing price on September 2, 2026, was 14.06 USD, down 0.85% from 14.18 USD recorded on September 1, 2026.

The same overview indicates that MGTX stock has declined 4.96% over the last five trading days but remains up 78.14% since the start of 2026, highlighting the volatility around the recent Q2 2026 release.

Technical data from the MeiraGTx charts section on Zonebourse show that MGTX trades on the Nasdaq with a last quoted level of 14.06 USD and reported volume of 8.85 million USD equivalent for the same closing session.

Go deeper

More details on MGTX fundamentals and stock history

For investors who want to explore longer-term figures, historical annual accounts and additional market data for MeiraGTx are available via the issuer overview and related documents.

More MeiraGTx stock coverage Investor Relations

Gene therapy pipeline as business driver

MeiraGTx focuses on gene therapy programs targeting inherited retinal diseases and other serious conditions, and the Q2 2026 revenue spike reflects milestone and collaboration payments rather than a broad commercial product rollout.

Pipeline progress and potential future licensing or partnership deals are likely to remain key drivers for MGTX stock, especially after the company shifted from a loss in Q1 2026 to a positive earnings figure in Q2 2026.

Latest price level for MGTX stock

Based on the latest available closing data from the CBOE and Nasdaq quotation pages aggregated on Zonebourse, MGTX stock closed at 14.06 USD on September 2, 2026, with the same price level reported across both trading venues.